中华放射学杂志
中華放射學雜誌
중화방사학잡지
Chinese Journal of Radiology
2009年
6期
656-660
,共5页
肝肿瘤%血管生成抑制剂
肝腫瘤%血管生成抑製劑
간종류%혈관생성억제제
Liver neoplasms%Angiogenesis inhlbitors
目的 探讨应用沙利度胺后小鼠肝脏微小转移瘤内血管的形态学变化规律.方法 20只BALB/c小鼠制成肝转移瘤模型,并将其按体重分层随机方法分为对照组和实验组.从注入结肠癌细胞后第1天开始连续14 d,对实验组小鼠每天腹腔内注射沙利度胺200 mg/kg,对照组小鼠每天腹腔内注射相同剂量的生理盐水.注射后第15天,采用活体荧光显微镜对2组小鼠的肿瘤最大直径在相似范围内的肝脏微小转移瘤(实验组26个、对照组27个)进行活体观察.动物处死后,保留肝脏,采用抗CD34单克隆抗体进行免疫组织化学染色,分别将实验组52个、对照组55个转移瘤按肿瘤最大直径(以400μm为界)分为大小2组,采用t检验比较各组间肿瘤内微血管密度(MVD)、肿瘤内血管分支密度(BD)和肿瘤内CD34阳性血管密度(MVD-CD34).结果 对照组中较大转移瘤的MVD和MVD-CD34[分别为(18.1±3.5)%和(22.9±2.8)条血管/高倍视野]高于小转移瘤[分别为(13.0±3.2)%和(12.8±2.5)条血管/高倍视野],t值分别为和2.840和9.860,P值均<0.01;而BD差异无统计学意义[大、小转移瘤BD分别为(110.0±20.5)和(99.7±17.3)条/lmm2,t=1.040,P＞0.05)].实验组中只有较大转移瘤的MVD-CD34[(17.4±2.3)条血管/高倍视野]高于小转移瘤[(11.5±2.5)条血管/高倍视野](t=8.770,P<0.01),而MVD和BD差异均尤统计学意义,大、小转移瘤MVD分别为(14.7±3.5)%和(13.2±3.3)%,BD分别为(95.3±18.3)和(97.1±21.O)条/mm2,t值分别为0.826和0.347,P值均>0.05.实验组与对照组间比较,可见小转移瘤的MVD、MVD-CD34和BD差异无统计学意义(t值分别为0.098、1.190和0.392,P值均>0.05),而实验组较大转移瘤的MVD、MVD-CD34和BD均明显小于对照组(t值分别为3.140、9.850和2.870,P值均<0.01).结论 沙利度胺只对具有新生血管的肝脏微小转移瘤表现出抗血管新生作用,而且肿瘤内不同血管成分对抗血管新生治疗反应不同.
目的 探討應用沙利度胺後小鼠肝髒微小轉移瘤內血管的形態學變化規律.方法 20隻BALB/c小鼠製成肝轉移瘤模型,併將其按體重分層隨機方法分為對照組和實驗組.從註入結腸癌細胞後第1天開始連續14 d,對實驗組小鼠每天腹腔內註射沙利度胺200 mg/kg,對照組小鼠每天腹腔內註射相同劑量的生理鹽水.註射後第15天,採用活體熒光顯微鏡對2組小鼠的腫瘤最大直徑在相似範圍內的肝髒微小轉移瘤(實驗組26箇、對照組27箇)進行活體觀察.動物處死後,保留肝髒,採用抗CD34單剋隆抗體進行免疫組織化學染色,分彆將實驗組52箇、對照組55箇轉移瘤按腫瘤最大直徑(以400μm為界)分為大小2組,採用t檢驗比較各組間腫瘤內微血管密度(MVD)、腫瘤內血管分支密度(BD)和腫瘤內CD34暘性血管密度(MVD-CD34).結果 對照組中較大轉移瘤的MVD和MVD-CD34[分彆為(18.1±3.5)%和(22.9±2.8)條血管/高倍視野]高于小轉移瘤[分彆為(13.0±3.2)%和(12.8±2.5)條血管/高倍視野],t值分彆為和2.840和9.860,P值均<0.01;而BD差異無統計學意義[大、小轉移瘤BD分彆為(110.0±20.5)和(99.7±17.3)條/lmm2,t=1.040,P＞0.05)].實驗組中隻有較大轉移瘤的MVD-CD34[(17.4±2.3)條血管/高倍視野]高于小轉移瘤[(11.5±2.5)條血管/高倍視野](t=8.770,P<0.01),而MVD和BD差異均尤統計學意義,大、小轉移瘤MVD分彆為(14.7±3.5)%和(13.2±3.3)%,BD分彆為(95.3±18.3)和(97.1±21.O)條/mm2,t值分彆為0.826和0.347,P值均>0.05.實驗組與對照組間比較,可見小轉移瘤的MVD、MVD-CD34和BD差異無統計學意義(t值分彆為0.098、1.190和0.392,P值均>0.05),而實驗組較大轉移瘤的MVD、MVD-CD34和BD均明顯小于對照組(t值分彆為3.140、9.850和2.870,P值均<0.01).結論 沙利度胺隻對具有新生血管的肝髒微小轉移瘤錶現齣抗血管新生作用,而且腫瘤內不同血管成分對抗血管新生治療反應不同.
목적 탐토응용사리도알후소서간장미소전이류내혈관적형태학변화규률.방법 20지BALB/c소서제성간전이류모형,병장기안체중분층수궤방법분위대조조화실험조.종주입결장암세포후제1천개시련속14 d,대실험조소서매천복강내주사사리도알200 mg/kg,대조조소서매천복강내주사상동제량적생리염수.주사후제15천,채용활체형광현미경대2조소서적종류최대직경재상사범위내적간장미소전이류(실험조26개、대조조27개)진행활체관찰.동물처사후,보류간장,채용항CD34단극륭항체진행면역조직화학염색,분별장실험조52개、대조조55개전이류안종류최대직경(이400μm위계)분위대소2조,채용t검험비교각조간종류내미혈관밀도(MVD)、종류내혈관분지밀도(BD)화종류내CD34양성혈관밀도(MVD-CD34).결과 대조조중교대전이류적MVD화MVD-CD34[분별위(18.1±3.5)%화(22.9±2.8)조혈관/고배시야]고우소전이류[분별위(13.0±3.2)%화(12.8±2.5)조혈관/고배시야],t치분별위화2.840화9.860,P치균<0.01;이BD차이무통계학의의[대、소전이류BD분별위(110.0±20.5)화(99.7±17.3)조/lmm2,t=1.040,P＞0.05)].실험조중지유교대전이류적MVD-CD34[(17.4±2.3)조혈관/고배시야]고우소전이류[(11.5±2.5)조혈관/고배시야](t=8.770,P<0.01),이MVD화BD차이균우통계학의의,대、소전이류MVD분별위(14.7±3.5)%화(13.2±3.3)%,BD분별위(95.3±18.3)화(97.1±21.O)조/mm2,t치분별위0.826화0.347,P치균>0.05.실험조여대조조간비교,가견소전이류적MVD、MVD-CD34화BD차이무통계학의의(t치분별위0.098、1.190화0.392,P치균>0.05),이실험조교대전이류적MVD、MVD-CD34화BD균명현소우대조조(t치분별위3.140、9.850화2.870,P치균<0.01).결론 사리도알지대구유신생혈관적간장미소전이류표현출항혈관신생작용,이차종류내불동혈관성분대항혈관신생치료반응불동.
Objective To investigate the morphological change of intratumoral microvessels after administration of thalidomide in the murine hepatic metastases. Methods Among 20 mice with hepatic metastases created by injection of colon-26 tumor cells into the spleen, 10 were treated with thalidomide (200 mg/kg) by intraperitoneal injection daily, the other 10 were treated with saline only by intraperitoneal injection daily. Fifteen days after inoculation of tumor cell, the intratumoral mierovessel of hepatic metastases with similar size in both groups were studied with in vivo microscopy (26 and 27 neoplasms in experimental group and control group respectively ) and immunohistochemistry for CD34 (52 and 55 neoplasms in experimental group and control group respectively). Two-tailed student t test was used to determine differences in intratumoral microvessel density (MVD), intratumoral branch density (BD) and CD34 positive intratumoral microvessel density (MVD-CD34) between the small ( < 400 μm in diameter) and large metastases in both groups, and that between thalidomide treated group and control group. Results For the control group, although the MVD and MVD-CD34 of larger metastases was more than that of small metastases respectively [(18.1±3.5)% vs (13.0±3.2) %, t =2.840,P<0.01;(22.9±2.8)vs ( 12. 8±2. 5) vessels per field, t = 9. 860, P < 0. 01 ], the BD was similar to that of small metastases [(110.0±20.5)vs(99.7±17.3) branches/rnm2, t = 1.040,P >0.05]. For the thalidomide treated group, despite the MVD-CD34 of larger metastases was more than that of small metastases [ ( 17.4±2. 3)vs (11.5±2. 5 ) vessels per field, t = 8. 770, P < 0. 01], the MVD and BD was similar to that of small metastases respectively [(14.7±3.5)% vs(13.2±3.3) %, t =0.826,P >0.05; (95.3±18.3)vs (97. 1±21. 0)branches/mm2,t=0. 347,P>0. 05]. The MVD, BD and MVD-CD34 of small metastases were similar to each other between two groups ( t = 0. 098, 0. 392,1. 190; P > 0. 05 ), however, that of large metastases were significantly lower in thalidomide treated group than in control group ( t = 3. 140,2. 870, 9. 850;P < 0. 01 ). Conclusions Thalidomide exerts antiangiogenic effect on the hepatic metastases with angiogenesis only, and the different vascular components in the tumor vasculature demonstrate variousresponses to antiangiogenic therapy.
